Log In
BCIQ
Print this Print this
 

RSV mAb (D25, MEDI8897)

  Manage Alerts
Collapse Summary General Information
Company AIMM Therapeutics B.V.
DescriptionHuman IgG1 kappa mAb against respiratory syncytial virus (RSV)
Molecular Target RSV F protein
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationRespiratory syncytial virus (RSV)
Indication DetailsPrevent lower respiratory tract infection caused by respiratory syncytial virus (RSV); Treat respiratory syncytial virus (RSV)
Regulatory Designation U.S. - Fast Track (Prevent lower respiratory tract infection caused by respiratory syncytial virus (RSV))
PartnerAstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today